pneumococcal polysaccharide serotype 1-CRM197 conjugate adsorbed on aluminium phosphate

This drug is a monovalent pneumococcal conjugate vaccine (PCV) candidate or component consisting of the capsular polysaccharide of *Streptococcus pneumoniae* serotype 1 covalently linked to the CRM197 carrier protein and adsorbed onto an aluminium phosphate adjuvant. Developed by the Rijksinstituut voor Volksgezondheid en Milieu (RIVM), this conjugate is designed to enhance the immunogenicity of the polysaccharide by invoking a T-cell dependent immune response, which is essential for establishing long-term immunological memory and efficacy in infants. Serotype 1 is a significant cause of invasive pneumococcal disease globally, particularly in regions such as Africa and Asia. This specific formulation has been utilized in clinical trials to evaluate the safety and immunogenicity of the RIVM-developed PCV technology, which has subsequently been transferred to various international manufacturers to facilitate the production of affordable multi-valent vaccines for global health initiatives.

Other names

monovalent pneumococcal conjugate vaccine serotype 1Pn1-CRMPn-1-CRMPn 1-CRM